Highest-materiality recent filing
Intuitive Surgical boosts buyback to $5.0B; shareholders approve plan amendment
Board increased stock repurchase authorization to $5.0B aggregate, including prior remaining balance.
Intuitive Q1 rev $2.77B (+23%), EPS $2.50 non-GAAP; procedures +17%, da Vinci placements 431
Revenue $2.77B (+23% YoY); GAAP EPS $2.28, non-GAAP EPS $2.50 (vs. $1.92/$1.81 prior year).
Intuitive Surgical completes acquisition of European distributors, expands direct ops in 5 countries
Acquisition closed March 1, 2026, of da Vinci and Ion distribution business from ab medica, Abex, Excelencia Robótica.
Q4 revenue $2.87B (+19% YoY); GAAP net income $795M ($2.21 diluted EPS); non-GAAP net income $914M ($2.53 diluted EPS).
Intuitive Surgical Q4 2025 revenue $2.87B, up 19% YoY; procedures grow 18%
Revenue $2.87B in Q4 (+19% YoY); full year $10.06B (+21%).
Intuitive Surgical Q3 revenue $2.51B (+23% YoY); EPS $1.95 GAAP / $2.40 non-GAAP; procedures +20%
Worldwide procedures grew ~20% YoY; da Vinci +19%, Ion +52%.
Intuitive Surgical Q2 revenue up 21% to $2.44B; non-GAAP EPS $2.19 vs $1.78
Revenue $2.44B (+21% YoY); GAAP diluted EPS $1.81; non-GAAP diluted EPS $2.19 (vs $1.46/$1.78 last year).
Intuitive Surgical promotes President Dave Rosa to CEO effective July 1, 2025
David J. Rosa promoted to CEO effective July 1, 2025; he previously served as President.
Board increased stock repurchase authorization to $4.0B aggregate, including prior remaining amounts.
Intuitive Q1 revenue $2.25B, EPS $1.92; procedure volume +17%
Revenue $2.25B (+19% YoY); GAAP EPS $1.92, non-GAAP EPS $1.81.
Intuitive Q4 beats: rev $2.41B, adj EPS $2.21; buys Euro distributors for ~€321M
Q4 da Vinci procedures grew ~18% YoY; 493 systems placed including 174 da Vinci 5.
Intuitive Q4 rev $2.41B (+25% YoY), procedures +18%; guides 2025 procedure growth 13-16%
Q4 preliminary revenue $2.41B, up 25% YoY; full-year 2024 revenue $8.35B, up 17%.
Intuitive Surgical Q3 revenue $2.04B (+17% YoY); GAAP EPS $1.56, non-GAAP $1.84
da Vinci procedures grew 18% YoY; placed 379 systems including 110 da Vinci 5 units.
Intuitive Surgical Q2 revenue $2.01B (+14% YoY), GAAP EPS $1.46, non-GAAP $1.78
Revenue $2.01B (+14% YoY); GAAP net income $527M ($1.46 EPS), non-GAAP $641M ($1.78 EPS).
Taylor Patton, Global Senior Vice President, Endoluminal will succeed Mr. Charlton as the Company’s Chief Commercial and Marketing Officer.
Effective July 1, 2026, Henry L. Charlton will transition from his role as Chief Commercial and Marketing Officer of Intuitive Surgical, Inc. (the “Company”) and begin serving as Senior Vice President of Global Business Operations of the Company.
On May 14, 2025, the Board of Directors (the “Board”) of Intuitive Surgical, Inc. (the “Company”) appointed David J. Rosa, currently the Company’s President, as Chief Executive Officer of the Company effective July 1, 2025.
the independent directors of the Board appointed Craig H. Barratt, Ph.D., the Board’s current Chair, to serve as the lead independent director of the Board also effective July 1, 2025.
Mr. Rosa will replace Gary S. Guthart, Ph.D., who will step down as Chief Executive Officer of the Company effective July 1, 2025 and will assume the position of Executive Chair of the Board as of that same date, and will continue to serve as a director.
Effective January 1, 2025, Jamie E. Samath was promoted to serve as Executive Vice President, Chief Financial Officer and Head of Business Technology of Intuitive Surgical, Inc. (the “Company”).
In addition, effective January 1, 2025, Henry L. Charlton was promoted to serve as Executive Vice President, Chief Commercial and Marketing Officer of the Company.
On July 24, 2024, the Board of Directors (the “Board”) of Intuitive Surgical, Inc. (the “Company”) appointed David J. Rosa to the Board effective as of July 24, 2024.
Max materiality 0.85 · Median 0.78 · Most common event earnings